Efficacy and safety of tacrolimus in systemic lupus erythematosus patients with refractory thrombocytopenia: a retrospective study

Abstract

Objective

We evaluated the efficacy and safety of tacrolimus in systemic lupus erythematosus patients with refractory thrombocytopenia.

Methods

We retrospectively reviewed the data for 20 systemic lupus erythematosus patients with refractory thrombocytopenia and treated with tacrolimus during the period January 2013 to January 2015. In addition to glucocorticoids, all patients were treated with tacrolimus, 1 mg taken twice daily. The clinical effect of tacrolimus treatment in patients was evaluated by analysis of platelet counts at baseline and after one, three and six months of tacrolimus treatment. Levels of anti-double-stranded DNA antibodies and complement C3, C4 were determined individually.

Results

After one month of tacrolimus treatment, three patients (15%) did not respond, three patients (15%) achieved a complete response and the other 14 patients (75%) achieved a partial response. After three months of tacrolimus treatment, the platelet counts of all patients were significantly improved. A partial response was seen in 14 patients (75%) and the complete response rate increased to 25% (five patients). After six months, all patients attained partial response or complete response without relapse, and the rate of complete response increased to 75%. Compared to pretreatment, anti-double-stranded DNA antibody levels and the disease activity index score were markedly decreased after tacrolimus treatment. The levels of serum C3 and C4 were increased significantly (P < 0.05).

Conclusions

Our survey revealed that a six-month course of tacrolimus is a safe and effective treatment for systemic lupus erythematosus patients with refractory thrombocytopenia.

Keywords

Tacrolimus systemic lupus erythematosus thrombocytopenia

Get full access to this article

View all access options for this article.

References

Gurevitz

Snyder

Wessel

et al.

Systemic lupus erythematosus: a review of the disease and treatment options. Consult Pharm 2013; 28: 110–121.

Mok

Lee

et al.

A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford) 2000; 39: 399–406.

Ktona

Barbullushi

Backa

et al.

Evaluation of thrombocytopenia in systemic lupus erythematosus and correlation with different organs damages. Mater Sociomed 2014; 26: 122–124.

Kwok

Cho

et al.

Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study. Lupus 2009; 18: 16–21.

Zhuang

Zou

et al.

A clinical comparative study on treatment of severe newly diagnosed immune thrombocytopenia by recombinant human thrombopoietin combined with glucocorticoid. Zhonghua Xueyexue Zazhi 2013; 34: 883–886.

Ödek

Kendirli

Yaman

et al.

Cyclosporine-associated thrombotic microangiopathy and thrombocytopenia-associated multiple organ failure: a case successfully treated with therapeutic plasma exchange. J Pediatr Hematol Oncol 2014; 36: e88–e90.

Park

Kim

Song

et al.

Application of vincristine-loaded platelet therapy in three dogs with refractory immune-mediated thrombocytopenia. J Vet Sci 2015; 16: 127–130.

Liu

Wang

et al.

Splenectomy for thrombocytopenia associated with systemic lupus erythematosus in 11 Chinese patients. Rheumatol Int 2011; 31: 9–15.

Patel

Cook

Greenhalgh

et al.

Overview of extended release tacrolimus in solid organ transplantation. World J Transplant 2016; 6: 144–154.

10.

Veenhof H, Koster RA, Alffenaar JC, et al. Clinical validation of simultaneous analysis of tacrolimus, cyclosporine A and creatinine in dried blood spots in kidney transplant patients. Transplantation. Epub ahead of print 1 December 2016. DOI: 10.1097/TP.0000000000001591.

11.

Yoon

. Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review. J Biomed Biotechnol 2010; 2010: 686480–686480.

12.

Miyasaka

Kawai

Hashimoto

. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled doubleblind multicenter study. Mod Rheumatol 2009; 19: 606–615.

13.

Duddridge

Powell

. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 1997; 56: 690–692.

14.

Watanabe

Yamanaka

Sada

et al.

The efficacy of add-on tacrolimus for minor flare in patients with systemic lupus erythematosus: a retrospective study. Lupus 2016; 25: 54–60.

15.

Boctor

. Tacrolimus (FK506) associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in lung transplant salvage with a plasmapheresis and cyclosporin. Egypt J Immunol 2006; 13: 95–99.

16.

Arai

Kuramitsu

Fukumoto

et al.

A case report of drug-induced thrombocytopenia after living donor liver transplantation. Kobe J Med Sci 2016; 62: E9–E12.

17.

Schoettler

Elisofon

Kim

et al.

Treatment and outcomes of immune cytopenias following solid organ transplant in children. Pediatr Blood Cancer 2015; 62: 214–218.

18.

Ernestho-ghoud

Rahamefy

Ranaivo

et al.

Acquired amegakaryocytic thrombocytopenia purpura: think of systemic lupus erythematosus. Pan Afr Med J 2015; 20: 86–86.

19.

Ren

Yang

et al.

Tolerogenic dendritic cells modified by tacrolimus suppress CD4(+) T-cell proliferation and inhibit collagen-induced arthritis in mice. Int Immunopharmacol 2014; 21: 247–254.

20.

Jiang

et al.

The clinical characteristics of macrophage activation syndrome secondary to systemic lupus erythematosus. Zhonghua Neike Zazhi 2016; 55: 840–844.

21.

Gijsen

Madadi

Dube

et al.

Tacrolimus-induced nephrotoxicity and genetic variability: a review. Ann Transplant 2012; 17: 111–121.

22.

Ziakas

Poulou

Giannouli

et al.

Thrombocytopenia in lupus: baseline C3 as an independent risk factor for relapse. Ann Rheum Dis 2007; 66: 130–131.